Validation of necrotising infection clinical composite endpoint in a retrospective cohort of patients with necrotising soft tissue infections
Diving and Hyperbaric Medicine Journal · 2024
DOI: 10.28920/dhm54.3.155-161 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Diving and Hyperbaric Medicine Journal, 2024. Verfasst von Victoria Bion und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Intensive Care and Hyperbaric Medicine, Alfred Health, Melbourne, Australia. Hauptthemen laut MEDLINE: Soft Tissue Infections, Organ Dysfunction Scores. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
Rapidly progressive necrotising soft tissue infections (NSTIs) are associated with high mortality and morbidity. Low incidence and disease heterogeneity contribute to low event rates and inadequately powered studies. The Necrotising Infections Clinical Composite Endpoint (NICCE) provides a binary outcome with which to assess interventions for NSTIs. Partly with a view towards studies of hyperbaric oxygen treatment in NSTIs we aimed to validate NICCE in a retrospective cohort of NSTI patients.
Methods
Eligible patients were admitted between 2012 and 2021 to an adult major referral hospital in Victoria, Australia with surgically confirmed NSTI. The NICCE and its constituents were assessed in the whole cohort (n = 235). The cohort was divided into two groups using the modified sequential organ failure assessment (mSOFA) score, with an admission mSOFA score ≥ 3 defined as high acuity.
Results
Baseline characteristics of the whole (n = 235), the high (n = 188) and the low acuity cohorts (n = 47) were similar. Survival rates were high (91.1%). Patients with an admission mSOFA ≥ 3 were less likely to meet NICCE criteria for ‘success’ compared to the lower acuity cohort (34.1% and 64.7% respectively). Meeting NICCE criteria was significantly associated with lower resource utilisation, measured by intensive care unit days, ventilator days, and hospital length of stay for all patients and for those with high acuity on presentation.
Conclusions
The NICCE provides greater discriminative ability than mortality alone. It accurately selects patients at high risk of adverse outcomes, thereby enhancing feasibility of trials. Adaptation of NICCE to include patient-centred outcomes could strengthen its clinical relevance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Intensive Care and Hyperbaric Medicine, Alfred Health, Melbourne, Australia.
- School of Medicine, Monash University, Melbourne, Australia.
- Plastics, Hand and Faciomaxillary Surgery Unit, Alfred Health, Melbourne, Australia.
- School of Public Health and Preventative Medicine, Monash University, Melbourne, Australia.
- Emergency and Trauma Centre, Alfred Health, Melbourne, Australia.
- Corresponding author: Dr Bridget Devaney, Head of Hyperbaric Medicine, Alfred Health, 55 Commercial Road, Melbourne, VIC 3004, Australia, ORCiD: 0000-0001-6521-418X, b.devaney@alfred.org.au.
Zitieren
APA
Bion, V., Jape, D., Niesen, R., Angliss, M., Bruscino-Raiola, F., Mitra, B., & Devaney, B. (2024). Validation of necrotising infection clinical composite endpoint in a retrospective cohort of patients with necrotising soft tissue infections. Diving and Hyperbaric Medicine Journal. https://doi.org/10.28920/dhm54.3.155-161
Vancouver
Bion V, Jape D, Niesen R, Angliss M, Bruscino-Raiola F, Mitra B, et al. Validation of necrotising infection clinical composite endpoint in a retrospective cohort of patients with necrotising soft tissue infections. Diving and Hyperbaric Medicine Journal. 2024. doi:10.28920/dhm54.3.155-161
BibTeX
@article{Bion2024,
author = {Bion, Victoria and Jape, Dylan and Niesen, Rachel and Angliss, Margaret and Bruscino-Raiola, Frank and Mitra, Biswadev and Devaney, Bridget},
title = {Validation of necrotising infection clinical composite endpoint in a retrospective cohort of patients with necrotising soft tissue infections},
journal = {Diving and Hyperbaric Medicine Journal},
year = {2024},
doi = {10.28920/dhm54.3.155-161}
}
EUVIMED